BIOMAT Database Logo BIOMAT Database Logo

Protective effects of G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock. 1992

F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Institute of Pharmacology, University of Messina, Italy.

Splanchnic artery occlusion (SAO) shock was induced in anesthetized rats by clamping the celiac trunk and the superior mesenteric artery for 45 min. The arteries were then released and survival rate, mean survival time, mean arterial blood pressure (MAP), plasma levels of thromboxane B2 (TxB2) and 6-keto-PGF1 alpha, and the phagocytotic activity of peritoneal macrophages were evaluated. Shocked animals died within 89 +/- 10 min, while all sham-shocked rats survived greater than 3 h. SAO shock produced relevant changes in MAP, significantly increased plasma levels of TxB2 and 6-keto-PFG1 alpha, and decreased peritoneal macrophage phagocytotic activity. The administration of G 619, a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist (50 mg/kg, 15 min before SAO shock) significantly increased survival time (190 +/- 13 min) and survival rate, reduced plasma levels of TxB2, and partially restored the impairment in peritoneal macrophage phagocytosis. Finally, the administration of G 619 had beneficial effects on changes in MAP-induced bay SAO shock. These data further confirm the involvement of TxA2 in SAO shock and suggest that G 619 may have positive effects in low-flow states.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008297 Male Males
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D010847 Picolines A group of compounds that are monomethyl derivatives of pyridines. (From Dorland, 28th ed) Picoline
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011982 Receptors, Prostaglandin Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behavior of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin D2 (DP receptors), prostaglandin E2 (EP1, EP2, and EP3 receptors), prostaglandin F2-alpha (FP receptors), and prostacyclin (IP receptors). Prostaglandin Receptors,Prostaglandin Receptor,Receptor, Prostaglandin,Receptors, Prostaglandins,Prostaglandins Receptors
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001157 Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency. Arterial Obstructive Diseases,Arterial Occlusion,Arterial Obstructive Disease,Arterial Occlusions,Arterial Occlusive Disease,Disease, Arterial Obstructive,Disease, Arterial Occlusive,Obstructive Disease, Arterial,Occlusion, Arterial,Occlusive Disease, Arterial

Related Publications

F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock.
July 1988, Methods and findings in experimental and clinical pharmacology,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Protective effects of the specific thromboxane receptor antagonist (+)-S145Na in splanchnic artery occlusion shock in rats.
May 1990, The Journal of pharmacology and experimental therapeutics,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
[Thromboxane A2 synthase inhibitor and receptor antagonist].
October 2001, Nihon rinsho. Japanese journal of clinical medicine,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Beneficial effects of a specific leukotriene receptor antagonist in splanchnic artery occlusion shock.
June 1989, European journal of pharmacology,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
December 1993, British journal of pharmacology,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
March 1994, British journal of pharmacology,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Protective effects of ONO 3708, a new thromboxane A2 receptor antagonist, during experimental endotoxin shock.
May 1989, Circulatory shock,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.
May 2001, The Journal of pharmacy and pharmacology,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Protective effects of KW-3635, a novel thromboxane A2 antagonist, in murine traumatic shock.
June 1990, European journal of pharmacology,
F Squadrito, and D Altavilla, and B Zingarelli, and M P Ioculano, and G M Campo, and G Calapai, and A Saitta, and G Urna, and A Sardella, and G Spignoli
Protective effects of a novel 21-aminosteroid during splanchnic artery occlusion shock.
February 1990, Circulatory shock,
Copied contents to your clipboard!